KarinCA FRYS the SA assassin read her here and on SA...dont forget to like it!!!!!!!!!
Ben... I'm holding Cellceutix (CTIX.OB) long. I'm unafiliated with the company and receive no compensation other than what I may receive from Seeking Alpha from articles I write. I'm a full time trader that rarely holds. But, I've made an exception with this one after doing my own due diligence. I'm holding as an investor.
~~~~~~~~~
How much are two guys worth? Ideas and technologies can be worth billions. Ask Mark Zuckerberg how much his idea for Facebook was worth. Further, compounds are not merely ideas, they have intrinsic value.
~~~~~~~~~~
You might want to be careful shorting here since trial results may come out at any time. And, if they show kevetrin works on people even close to what it has done with animals your trade will go bad.
~~~~~~~~~~
Not only has kevetrin been found to be non toxic in the first cycle of dosing, the first cohort was advanced into an additional cyle. And, a second cohort started their first cycle on an increased dosage. You may not realize it, but, NOT showing toxicity normally seen in chemotherapy is extremely important in the development of any drug candidate.
~~~~~~~~~~
Four, not seven press releases have been put out by Cellceutix (CTIX.OB) in December. You may want to go back and do a recount.
~~~~~~~~~~
I'd like to know how the "peers" you mentioned are comparable to CTIX. You've chosen companies with far less potential and pipelines that pale in comparison.
~~~~~~~~~~
Self enrichment of management will only come with an increase in share value which will bring all shareholders along for the ride.
~~~~~~~~~~
A $5 million dollar burn rate is extraordinarily low for a biotech company.
~~~~~~~~~~
The mentioned Aspire deal gives them a $10 million equity line which means they've acheived their financial goal at reasonable terms.
~~~~~~~~~~
You may want to read the SEC filings closer. You'll see that the funding source has been Leo Ehrlich and Krishna Menon. (the 2 employees)
~~~~~~~~~~
No one benefits from dilution, certainly, not the primary shareholders and that's why the company has kept the dilution under control. There are very few shares out for a biotech at this stage.
~~~~~~~~~~
The two employees have have submitted a multi-thousand page IND to the FDA and applied for a trial at Dana Farber and Beth Israel (pretty sure that none of the “peers” you mentioned have ever conducted trials at world leading cancer centers like these), advanced Kevetrin into clinical trials at Dana-Farber and Beth Israel Deaconess, received FDA guidance to advance Prurisol into Phase 2/3 clinical trials, been approached to study Kevetrin in combination with Pfizer drugs, aligned clinical trials in Europe with another leading pharma cancer drugs and NOW been approached by another leading cancer center in the United States who wants to pay for more clinical trials. And, you say they haven't done much?!?
~~~~~~~~~~
Salary is accrued. For the year ended June 30, 2012, $9,990 was charged in development costs by Kard (Menon). These officers have done extremely well to manage finances and utilizing Kard Scientific, a CRO that is used by some of the biggest pharmaceutical companies in the U.S., is a prescient move to conserve monies. Would you rather they pay an outside institution?
~~~~~~~~~~
There are countless other companies with Class B shares, including the likes of Google and Berkshire Hathaway.
~~~~~~~~~~
$6,823,785 of the liabilities are due to officers for loans and salaries.
~~~~~~~~~~
Major pharmaceutical companies that have their eyes on Cellceutix will be looking for partnerships before the Aspire funding is used up.
~~~~~~~~~~
CTIX is not promoting the stock. There are simply a lot of excited shareholders due to them understanding the importance of p53 activation.
~~~~~~~~~~
You never even mentioned that Kevetrin is a drug that acts through the key p53 protein. I’m gathering that you don’t understand how big a p53 drug can be? Rather than me explaining p53 you should google it yourself. You clearly need to do a bit more due diligence.
~~~~~~~~~~
So is a company run by two guys worth $200 million? The answer is simply “Yes.”
Ben... I'm holding Cellceutix (CTIX.OB) long. I'm unafiliated with the company and receive no compensation other than what I may receive from Seeking Alpha from articles I write. I'm a full time trader that rarely holds. But, I've made an exception with this one after doing my own due diligence. I'm holding as an investor.
~~~~~~~~~
How much are two guys worth? Ideas and technologies can be worth billions. Ask Mark Zuckerberg how much his idea for Facebook was worth. Further, compounds are not merely ideas, they have intrinsic value.
~~~~~~~~~~
You might want to be careful shorting here since trial results may come out at any time. And, if they show kevetrin works on people even close to what it has done with animals your trade will go bad.
~~~~~~~~~~
Not only has kevetrin been found to be non toxic in the first cycle of dosing, the first cohort was advanced into an additional cyle. And, a second cohort started their first cycle on an increased dosage. You may not realize it, but, NOT showing toxicity normally seen in chemotherapy is extremely important in the development of any drug candidate.
~~~~~~~~~~
Four, not seven press releases have been put out by Cellceutix (CTIX.OB) in December. You may want to go back and do a recount.
~~~~~~~~~~
I'd like to know how the "peers" you mentioned are comparable to CTIX. You've chosen companies with far less potential and pipelines that pale in comparison.
~~~~~~~~~~
Self enrichment of management will only come with an increase in share value which will bring all shareholders along for the ride.
~~~~~~~~~~
A $5 million dollar burn rate is extraordinarily low for a biotech company.
~~~~~~~~~~
The mentioned Aspire deal gives them a $10 million equity line which means they've acheived their financial goal at reasonable terms.
~~~~~~~~~~
You may want to read the SEC filings closer. You'll see that the funding source has been Leo Ehrlich and Krishna Menon. (the 2 employees)
~~~~~~~~~~
No one benefits from dilution, certainly, not the primary shareholders and that's why the company has kept the dilution under control. There are very few shares out for a biotech at this stage.
~~~~~~~~~~
The two employees have have submitted a multi-thousand page IND to the FDA and applied for a trial at Dana Farber and Beth Israel (pretty sure that none of the “peers” you mentioned have ever conducted trials at world leading cancer centers like these), advanced Kevetrin into clinical trials at Dana-Farber and Beth Israel Deaconess, received FDA guidance to advance Prurisol into Phase 2/3 clinical trials, been approached to study Kevetrin in combination with Pfizer drugs, aligned clinical trials in Europe with another leading pharma cancer drugs and NOW been approached by another leading cancer center in the United States who wants to pay for more clinical trials. And, you say they haven't done much?!?
~~~~~~~~~~
Salary is accrued. For the year ended June 30, 2012, $9,990 was charged in development costs by Kard (Menon). These officers have done extremely well to manage finances and utilizing Kard Scientific, a CRO that is used by some of the biggest pharmaceutical companies in the U.S., is a prescient move to conserve monies. Would you rather they pay an outside institution?
~~~~~~~~~~
There are countless other companies with Class B shares, including the likes of Google and Berkshire Hathaway.
~~~~~~~~~~
$6,823,785 of the liabilities are due to officers for loans and salaries.
~~~~~~~~~~
Major pharmaceutical companies that have their eyes on Cellceutix will be looking for partnerships before the Aspire funding is used up.
~~~~~~~~~~
CTIX is not promoting the stock. There are simply a lot of excited shareholders due to them understanding the importance of p53 activation.
~~~~~~~~~~
You never even mentioned that Kevetrin is a drug that acts through the key p53 protein. I’m gathering that you don’t understand how big a p53 drug can be? Rather than me explaining p53 you should google it yourself. You clearly need to do a bit more due diligence.
~~~~~~~~~~
So is a company run by two guys worth $200 million? The answer is simply “Yes.”
ALWAYS TAKE YOUR BASIS OFF THE TABLE..........IF YOU OBEY THIS RULE YOU CAN NEVER LOSE YOUR ASS
The Magnificent Seven are CTIX CLSN THLD SNTA SBFM PCYC IMUC
The Magnificent Seven are CTIX CLSN THLD SNTA SBFM PCYC IMUC
